Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Medicines Company's cangrelor leads trio of CHMP opinions

This article was originally published in Scrip

Executive Summary

The Medicines Company is celebrating receiving three positive opinions from the EU's CHMP at its latest meeting this week, including for its antiplatelet agent Kengrexal (cangrelor), and its sealant powder Raplixa. Its antibiotic Orbactiv (oritavancin) was also one of two such products given marketing go-ahead by the committee (see, 23 January 2015).


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts